Major Depressive Disorder

New CDC survey data show an estimated 47 million adults in the US have ever been diagnosed with depression, with clear disparities based on demographics and regions.

An analysis of survey data from more than 50 health care workers in Massachusetts offers insight into the effects of the COVID-19 pandemic

Experiencing everyday discrimination is a significant predictor of sleep-related impairments among Black adults, highlighting the detrimental impact of discrimination.

“Our findings underline the importance of sleep health in treating depression as the nation battles the current mental health crisis,” investigators write.

A preference for eveningness was significantly associated with worse overall sleep difficulties, longer sleep latency, reduced sleep satisfaction, more prolonged sleep inertia, more daytime naps, and more severe depressive symptomatology.

The results show engagement in the Telehealth Collaborative Care program visits was greater compared to the Telehealth Enhanced Referral group.

Participants who only initiated non-stimulant therapy for ADHD had significantly greater odds of past-year prescription stimulant misuse than the population controls.

Patients with comorbid major depressive disorder were more likely to have a diagnoses of tobacco, alcohol, opioid, cannabis, stimulants, hallucinogens, sedatives-hypnotics, or anxiolytic use disorders compared to patients with only systemic lupus erythematous.

The rate of sleep apnea is greater in patients with bipolar disorder and depression.

The results show 26.3% of patients in the daily cannabis use only group endorsed 2 or more items on the symptom checklist, consistent with DSM-5 SUD, compared to 30.2% of the other drug use group and 51.8% of the daily cannabis and other drug use group.

A prospective cohort analysis of Denmark residents suggests correlation between cannabis overuse and risk of psychiatric conditions.

Data indicates that addressing mood disorders in patients not only improves mood symptoms but also demonstrates positive effects on certain cardiac events, suggesting benefits for both mental and physical well-being.

New prospective data show more adult patients achieved clinical response with ketamine than the historic standard ECT over a 6-month regimen.

Key opinion leaders at ATS 2023 urge physicians to treat more than just symptoms in patients with COPD and consider mood disorders and cardiac comorbidities.

Dr. Levine talks with Marketa Wills, MD, about the role of the payer in medicine.

An analysis of more than 1.8 million mother-offspring pairs offers new insight into a potential association between exposure to maternal depression/anxiety during pregnancy and risk of type 1 diabetes in offspring during adolescence.

There was an increase in depression in the cystic fibrosis group, as well as an increase in anxiety in cystic fibrosis caregivers during the pandemic.

Scores for the 20-Item Symptom Checklist improved from baseline over gestation in the interpersonal psychotherapy cohort, but not in the enhanced usual care group.

The results show depressive disorders in the first cohort were associated with a nearly 4-fold higher risk of depressive disorders in the spousal cohort.

State adoption of both SNAP eligibility policies, where the state eliminates the asset test and increases the income limit resulted in decreases in the rates of past-year major depressive episodes, mental illness, serious mental illness, and suicidal ideation.

Electroconvulsive therapy was superior to ketamine in a sensitivity analysis of methodologically stronger trials and also was better in study-defined response and remission for patients with major depressive episodes.

There was also significantly greater reductions in anxiety, Afghan-cultural distress symptoms, and psychiatric difficulties compared to the treatment as usual group.

There was a lower probability of initiating psycholeptics and having postpartum psychiatric emergencies in the early discontinuer and late discontinuer groups compared to the continuers.

Zuranolone is being evaluated as a 14 day, rapid-acting, once-daily, oral treatment for adult patients with MDD and PPD. The drug is an oral neuroactive steroid GABA-A receptor positive allosteric modulator.

The results show 28.9% of the aripiprazole augmentation group achieved remission, compared to 28.2% of the bupropion augmentation group and 19.3% of the bupropion switch group.